Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$4.4M
Filings
62
Firms Hired
3
Active Period
2017–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Expanding Access to Low-Cost Generics Act of 2023
2023 · second_quarter · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Client expense: $136,311 · Firm income: —
Matched citations: S. 1114
Expanding Access to Low-Cost Generics Act of 2023
2023 · second_quarter · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114).
Client expense: $136,311 · Firm income: —
Matched citations: S. 1114
Expanding Access to Low-Cost Generics Act of 2023
2023 · second_quarter · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Client expense: $136,311 · Firm income: —
Matched citations: S. 1114
Expanding Access to Low-Cost Generics Act of 2023
2023 · second_quarter · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Client expense: $136,311 · Firm income: —
Matched citations: S. 1114
Expanding Access to Low-Cost Generics Act of 2023
2023 · second_quarter · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Client expense: $136,311 · Firm income: —
Matched citations: S. 1114
Expanding Access to Low-Cost Generics Act of 2023
2023 · first_quarter · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114).
Client expense: $136,311 · Firm income: —
Matched citations: S. 1114
Expanding Access to Low-Cost Generics Act of 2023
2023 · first_quarter · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Client expense: $136,311 · Firm income: —
Matched citations: S. 1114
Expanding Access to Low-Cost Generics Act of 2023
2023 · first_quarter · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Client expense: $136,311 · Firm income: —
Matched citations: S. 1114
Expanding Access to Low-Cost Generics Act of 2023
2023 · first_quarter · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Client expense: $136,311 · Firm income: —
Matched citations: S. 1114
Expanding Access to Low-Cost Generics Act of 2023
2023 · first_quarter · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Client expense: $136,311 · Firm income: —
Matched citations: S. 1114
Patent Settlments BLOCKING Act (H.R. 938). Pharmaceutical Supply Chain Medicaid & Medicare
Client expense: $131,690 · Firm income: —
Matched citations: H.R. 938
Consolidated Appropriations Act, 2021
2020 · fourth_quarter · Firm: GOVERNMENT COUNSEL, LLC
H.R. 133-Consolidated Appropriations Act of 2021 relating to H.R. 938-The Blocking Act and S. 1895-Lower Health Care Costs Act (Section 205).
Client expense: — · Firm income: $30,000
Matched citations: H.R. 133
H.R. 133-Consolidated Appropriations Act of 2021 relating to H.R. 938-The Blocking Act and S. 1895-Lower Health Care Costs Act (Section 205).
Client expense: — · Firm income: $30,000
Matched citations: H.R. 938
Lower Health Care Costs Act
2020 · fourth_quarter · Firm: GOVERNMENT COUNSEL, LLC
H.R. 133-Consolidated Appropriations Act of 2021 relating to H.R. 938-The Blocking Act and S. 1895-Lower Health Care Costs Act (Section 205).
Client expense: — · Firm income: $30,000
Matched citations: S. 1895
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
Client expense: $116,690 · Firm income: —
Matched citations: H.R. 938
A bill for the relief of Jose Alberto Martinez Moreno, Micaela Lopez Martinez, and Adilene Martinez.
2020 · fourth_quarter · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
Client expense: $116,690 · Firm income: —
Matched citations: S. 794
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
Client expense: $91,158 · Firm income: —
Matched citations: H.R. 938
A bill for the relief of Jose Alberto Martinez Moreno, Micaela Lopez Martinez, and Adilene Martinez.
2020 · third_quarter · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
Client expense: $91,158 · Firm income: —
Matched citations: S. 794
William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021
2020 · third_quarter · Firm: GOVERNMENT COUNSEL, LLC
Department of Defense procurement activities; H.R. 6395- William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 relating to country of origin definition.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6395
H.R. 938-The Blocking Act; S. 1895-Lower Health Care Costs Ac (Sec.205).
Client expense: — · Firm income: $30,000
Matched citations: H.R. 938
Lower Health Care Costs Act
2020 · third_quarter · Firm: GOVERNMENT COUNSEL, LLC
H.R. 938-The Blocking Act; S. 1895-Lower Health Care Costs Ac (Sec.205).
Client expense: — · Firm income: $30,000
Matched citations: S. 1895
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
Client expense: $221,895 · Firm income: —
Matched citations: H.R. 938
A bill for the relief of Jose Alberto Martinez Moreno, Micaela Lopez Martinez, and Adilene Martinez.
2020 · second_quarter · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
Client expense: $221,895 · Firm income: —
Matched citations: S. 794
H.R. 938-The Blocking Act; H.R. 987-Strengthening Health Care and Lowering Prescription Drug Costs; S. 1895-Lower Health Care Costs Ac (Sec.205). Issues relating to COVID medical donations to the NIH and Strategic National Stockpile. Issues relating to onshoring pharmaceutical manufacturing.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 938
Strengthening Health Care and Lowering Prescription Drug Costs Act
2020 · second_quarter · Firm: GOVERNMENT COUNSEL, LLC
H.R. 938-The Blocking Act; H.R. 987-Strengthening Health Care and Lowering Prescription Drug Costs; S. 1895-Lower Health Care Costs Ac (Sec.205). Issues relating to COVID medical donations to the NIH and Strategic National Stockpile. Issues relating to onshoring pharmaceutical manufacturing.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 987
Source: Senate LDA